Longevity of hybrid immunity against SARS-CoV-2 in adults vaccinated with an adenovirus-based COVID-19 vaccine
This study confirms that hybrid immunity provides durable broadly cross-reactive antibody immunity against SARS-CoV-2 variants of concern for at least a year (360 days), and that it is further augment by SARS-CoV-2 re-exposure.
Authors
- Alice Kalirani
- Ndaona Mitole
- Kondwani Jambo (ORCID: https://orcid.org/0000-0002-3195-2210)
- Memory Mvula
- Marah G. Chibwana (ORCID: https://orcid.org/0000-0002-8940-3855)
- Jonathan Mandolo (ORCID: https://orcid.org/0000-0003-0143-7469)
- Edwin Lisimba
- Fatima Mtonga
- Chisomo Jowati
- Precious Chigamba (ORCID: https://orcid.org/0009-0005-6337-2850)
Institutions
- University of Liverpool (GB)
- Liverpool School of Tropical Medicine (GB)
- Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MW)
- University of Oxford (GB)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2024-09-12
- DOI
- https://doi.org/10.1186/s12879-024-09891-z
- Citations
- 3
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- Medical Research Council